Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (4489)	8/17/2001 12:57:40 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

more cash than pipeline That's just about every big pharma. <g> But what they are all looking for is late-stage pipeline. My guess is the Bayer stuff is mostly very early. BTW, a comment I saw someplace claimed that Bayer had just hired a bunch of contract salespeople to promote Baycol. So likely one of the contract companies will be hurt by this as well. Edit: I just found this in a PDII 8-k: Recent Developments On August 8, 2001, Bayer Corporation announced that it was voluntarily withdrawing Baycol from the U.S. market. PDI confirmed that it has an agreement with Bayer, pursuant to which its sales force markets three different products on Bayer's behalf, including Baycol. Based upon PDI's most recent discussions with Bayer, Bayer has informed PDI that it has no present intention of modifying its contract with PDI at this time, although Bayer has a contractual right to terminate the contract upon 75 days written notice. Peter